ABVC BioPharma, Inc.
$1.3
▲
0.93%
2026-04-21 05:01:01
www.abvcpharma.com
NCM: ABVC
Explore ABVC BioPharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$33.58 M
Current Price
$1.3
52W High / Low
$5.48 / $0.81
Stock P/E
—
Book Value
$0.46
Dividend Yield
—
ROCE
-48%
ROE
-1.19%
Face Value
—
EPS
$-0.39
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
16
Beta
0.38
Debt / Equity
26.12
Current Ratio
0.41
Quick Ratio
0.41
Forward P/E
-3.25
Price / Sales
—
Enterprise Value
$40.25 M
EV / EBITDA
-5.65
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Praxis Precision Medicines, Inc. | $340.84 | — | $9.47 B | — | -37.15% | -45.83% | $356 / $28.79 | $34.85 |
| 2. | IO Biotech, Inc. | $0.01 | — | $0.55 M | — | -197.41% | -2.4% | $2.79 / $0.01 | $0.01 |
| 3. | ACADIA Pharmaceuticals Inc. | $22.09 | 9.63 | $3.77 B | — | 8.14% | 39.89% | $28.35 / $14.08 | $7.21 |
| 4. | GT Biopharma, Inc. | $0.37 | — | $11.72 M | — | -214.65% | -13.77% | $3.85 / $0.35 | $0.23 |
| 5. | Axsome Therapeutics, Inc. | $184.13 | — | $9.35 B | — | -54.42% | -2.52% | $191.5 / $96.09 | $1.74 |
| 6. | OmniAb, Inc. | $1.55 | — | $237.44 M | — | -24.23% | -23.36% | $2.29 / $1.22 | $1.85 |
| 7. | Exelixis, Inc. | $46.57 | 16.78 | $11.84 B | — | 36.6% | 35.53% | $49.62 / $33.76 | $8.23 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | -0.8 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.99 M | -1.96 M | -2.29 M | -0.69 M | -0.33 M | — |
| Net Profit | -3.56 M | -2.04 M | -2.26 M | -0.84 M | 0.23 M | — |
| EPS in Rs | -0.14 | -0.08 | -0.09 | -0.03 | 0.01 | -0.03 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0.51 M | 0.15 M | 0.97 M |
| Operating Profit | -7.15 M | -4.71 M | -6.77 M | -15.11 M |
| Net Profit | -7.91 M | -4.9 M | -7.79 M | -16.42 M |
| EPS in Rs | -0.31 | -0.19 | -0.3 | -0.64 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 21.06 M | 7.54 M | 7.78 M | 9.58 M |
| Total Liabilities | 7.76 M | 6.82 M | 6.53 M | 6.34 M |
| Equity | 11.11 M | 1.23 M | 1.55 M | 3.1 M |
| Current Assets | 2.5 M | 2.18 M | 1.66 M | 2.99 M |
| Current Liabilities | 6.16 M | 6.56 M | 6.1 M | 5.54 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -2.99 M | -1.81 M | -4.19 M | -7.4 M |
| Investing CF | -1.21 M | 0 M | -0.36 M | -1.72 M |
| Financing CF | 4.64 M | 1.98 M | 3.87 M | 4.01 M |
| Free CF | -2.99 M | -1.81 M | -4.21 M | -7.52 M |
| Capex | — | — | -0.02 M | -0.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 234.31% | -84.28% | — | — |
| Earnings Growth % | 37.05% | 52.58% | — | — |
| Profit Margin % | -962.12% | -5109.26% | -1693.5% | — |
| Operating Margin % | -923.34% | -4439.24% | -1558.54% | — |
| Gross Margin % | 99.85% | -98.15% | 70.47% | — |
| EBITDA Margin % | -852.21% | -4153.24% | -1567.03% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-07-25 | 1:0.1 |